# Study to Evaluate the Safety and Immunogenicity of a Pandemic Influenza Vaccine in Adults Aged Between 18 and 60 Years

> **NCT00309634** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 400 (actual)

## Conditions studied

- Influenza

## Interventions

- **BIOLOGICAL:** 4 adjuvanted pandemic influenza candidate vaccines
- **BIOLOGICAL:** 4 non-adjuvanted pandemic influenza candidate vaccines

## Key facts

- **NCT ID:** NCT00309634
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-03-27
- **Primary completion:** 2006-10-28
- **Final completion:** 2006-10-28
- **Target enrollment:** 400 (ACTUAL)
- **Last updated:** 2017-05-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00309634

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00309634, "Study to Evaluate the Safety and Immunogenicity of a Pandemic Influenza Vaccine in Adults Aged Between 18 and 60 Years". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00309634. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*